Skip to main content

Table 1 Characteristics of manuscripts studied and outcome series extracted (Continued)

From: Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer

  Manuscripts, N = 115 DLT series, N = 155 OR series, N = 93
Colorectal cancer   1 (0.6%) 1 (1.1%)
Gynaecological cancer   1 (0.6%) 1 (1.1%)
B-cell malignancies   0 (0%) 1 (1.1%)
Not disclosed   1 (0.6%) 0 (0%)
Pancreatic cancer   1 (0.6%) 0 (0%)
Rectal cancer   1 (0.6%) 0 (0%)
Treatment undergoing dose-escalation    
Inhibitor   58 (37%) 43 (46%)
Chemotherapy   51 (33%) 25 (27%)
Chemotherapy + inhibitor   17 (11%) 12 (13%)
Monoclonal antibody   8 (5.2%) 0 (0.0%)
Immunomodulatory   4 (2.6%) 2 (2.2%)
Immunomodulatory + chemotherapy   3 (1.9%) 2 (2.2%)
Radiotherapy   4 (2.6%) 1 (1.1%)
Oncolytic virus   2 (1.3%) 2 (2.2%)
Radiopharmaceutical + inhibitor   2 (1.3%) 2 (2.2%)
Cell therapy   1 (0.6%) 2 (2.2%)
Antibody-drug conjugate   1 (0.6%) 1 (1.1%)
Cytokine   1 (0.6%) 1 (1.1%)
Chemoprevention   1 (0.6%) 0 (0%)
Gene therapy   1 (0.6%) 0 (0%)
Not disclosed   1 (0.6%) 0 (0%)
Treatment ensemble contains chemotherapy   91 (59%) 49 (53%)
Number of dose-levels   4 (2, 5) 4 (2, 5)